Infectious Diseases Physician and Researcher, University of Manchester. Interested in all aspergillosis clinical syndromes, invasive, allergic and chronic.
Manchester, UK
Joined May 2009
- Tweets668
- Following518
- Followers999
- Likes1.2K
Chris Kosmidis retweeted
In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months. Full SOLARIO trial results: nej.md/4dgrqwY
ALT This image shows a forest plot showing the robustness of the primary analysis results. Subgroups include definite treatment failure, definite or probable treatment failure, and definite, probable, or possible treatment failure. Hazard ratios with 95% confidence intervals are displayed, indicating whether a short duration is better than a long duration. A red line indicates the noninferiority margin.
Chris Kosmidis retweeted
Chronic aspergillosis sometimes occurs alongside other long-term lung conditions and infections
If you are affected by NTM (non-tuberculous Mycobacterium) and/or bronchiectasis, you can find out more with this online event aimed at patients and their families – at Manchester, England
Join @NJHealth on Sept 19, 2026, for the NTM & Bronchiectasis Patient & Family Course! Learn disease management and treatment advances.
Register: bit.ly/45UnIoX
#NTMAwareness #Bronchiectasis #LungHealth
Our review on COPD and aspergillus interaction just published in @TheLancetInfDis ! We highlight an under-recognised burden and major opportunities for prevention, earlier diagnosis and treatment.
pubmed.ncbi.nlm.nih.gov/4261…
@MFT_NAC
Chris Kosmidis retweeted
Congratulations to the @remap_cap investigators for conducting this important clinical trial, which will undoubtedly change clinical practice and treatment guidelines (or at least it should). Free link in first reply. @NEJM
Chris Kosmidis retweeted
NAC & @mimslearning offer a CPD course about #aspergillosis for GPs, to support them in managing patients with fungal lung conditions 🫁
#respiratory #GPs #pulmonary #respisbest #ABPA #MedEd #CME #NHS
Chris Kosmidis retweeted
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients - businesswire.com/news/home/2…
Chris Kosmidis retweeted
Would you like to do your #PhD in fungal lung infections? NAC accept applications all year round
✴️Personalised approach to antifungal treatment in chronic fungal lung disease✴️
👉More info at findaphd.com
#phdjobs #academicjobs #sciencejobs #Manchester #findaphd – at Sale, England
Chris Kosmidis retweeted
One-month treatment for latent tuberculosis.
Why aren't we using it? (Hint: We should.) @NEJM @NEJMClinician
voices.nejm.org/doi/full/10.…
Chris Kosmidis retweeted
UCB therapeutics announces they will trial anti-IL17/IL-13 multispecific antibody therapy in bronchiectasis in 2026
The pipeline of new therapies coming into the bronchiectasis and COPD field is exciting to see and will ultimately be great for patients.
ucb.com/newsroom/press-relea…
Chris Kosmidis retweeted
🆕⚡🟢Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis
Higher pyrazinamide and isoniazid exposures and slow NAT2 acetylator status were independently associated with hepatotoxicity.
In multivariable analysis, only pyrazinamide exposure was associated with hepatotoxicity. Rifampicin exposure up to 20 mg/kg/day was not associated with hepatotoxicity, supporting its safe use. #IDXposts academic.oup.com/cid/article…
Chris Kosmidis retweeted
Don't worry if you missed #WorldAspergillosisDay - the recordings are now online: youtube.com/@nationalaspergi…
Huge thanks to everyone who attended, hope to see you all again next year!
#IDtwitter #medtwitter #respiratory #respisbest #NHS @ckosmidis @MycologyRefManc @aspertrust – at Manchester, England
Chris Kosmidis retweeted
Today is #WorldAspergillosisDay - you can help by sharing this link with any GPs you know
NAC worked with MIMS to produce this CPD course for learning about #aspergillosis to help CPA and #ABPA be diagnosed and treated faster
#respiratory #GPs #pulmonary #respisbest – at Manchester, England
Aspergillus is a mould that is often seen in damp homes, and exposure can lead to #aspergillosis. This module, by specialists from the National Aspergillosis Centre (@MFT_NAC), looks at the diagnosis and management of the condition. buff.ly/rDAuxW9
Our new paper in Mycoses: Aspergillus serology predicts relapse in chronic pulmonary aspergillosis (#CPA).
End-of-therapy ↑IgG and Aspergillus sensitisation predicted relapse.
👉 Towards personalised follow-up in CPA
pubmed.ncbi.nlm.nih.gov/4161…
@MFT_NAC @eurconfmedmycol
Chris Kosmidis retweeted
Only 4 days until #WorldAspergillosisDay - have you registered? 🫁
➡️ eventbrite.co.uk/e/198070713…
Pls retweet!
@ckosmidis #respiratory @aspertrust @gaffi_org #ABPA #aspergilloma #idtwitter @EuropeanLung @BTSrespiratory @asthmalunguk @AFWGonline @MycologyRefManc @MRCcmm @MMSNIG – at Manchester, England
Looking forward to our 2026 World Aspergillosis Day event!
Being diagnosed with #aspergillosis can feel isolating and scary
Join the National Aspergillosis Centre (NHS) on Tues 3rd Feb for a free online patient meeting to share experiences, tips and research
#lunghealth #chronicillness @EuropeanLung #copd #abpa #aspergilloma #lungs
Chris Kosmidis retweeted
Registration for NAC's #WorldAspergillosisDay meeting is now open!
👉eventbrite.co.uk/e/198070713…
🗓️Tues 3 Feb
- Antifungal resistance
- CPA risk genes
- Adrenal insufficiency
- Current aspergillosis clinical trials
#idtwitter @aspertrust @MycologyRefManc @ckosmidis @UofMMFIG
🫁 Chronic pulmonary aspergillosis + OPAT
Our new JAC-AMR paper describes successful treatment with once-weekly rezafungin in a patient with #CPA, with improved convenience and potential cost savings vs daily echinocandins.
academic.oup.com/jacamr/arti…
@MFT_NAC
@MundipharmaTalk
Delighted to share we are recruiting for a Fully Funded PhD "Personalised Approach to Treatment of Chronic Fungal Lung Disease" at the @MFT_NAC and @FBMH_UoM as part of the MRC DTP studentship programme!
More info: findaphd.com/phds/project/mr…
Please get in touch before applying.
Chris Kosmidis retweeted
Delighted to share we are recruiting for a Fully Funded PhD "Personalised Approach to Treatment of Chronic Fungal Lung Disease" at the @MFT_NAC and @FBMH_UoM as part of the MRC DTP studentship programme!
More info: findaphd.com/phds/project/mr…
Please get in touch before applying.